These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83. High prevalence of plasmid-mediated quinolone resistance in escherichia coli strains producing extended-spectrum beta-lactamases isolated from faeces and urine of pregnant women with acute cystitis. Sohrabi M; Fathi J; Mohebi S; Hashemizadeh Z; Kholdi S; Hadadi M; Keshavarz K; Darvishvand Z Mol Biol Rep; 2024 Apr; 51(1):566. PubMed ID: 38656625 [TBL] [Abstract][Full Text] [Related]
84. Trends in prevalence of extended-spectrum beta-lactamase-producing Escherichia coli isolated from patients with community- and healthcare-associated bacteriuria: results from 2014 to 2020 in an urban safety-net healthcare system. Raphael E; Glymour MM; Chambers HF Antimicrob Resist Infect Control; 2021 Aug; 10(1):118. PubMed ID: 34380549 [TBL] [Abstract][Full Text] [Related]
85. Risk factors of urinary tract infection caused by extended spectrum β-lactamase-producing Escherichia coli in emergency department. Lee H; Han SB; Kim JH; Kang S; Durey A Am J Emerg Med; 2018 Sep; 36(9):1608-1612. PubMed ID: 29373168 [TBL] [Abstract][Full Text] [Related]
87. Clinical and bacteriological efficacy of pivmecillinam treatment for uncomplicated urinary tract infections caused by ESBL-producing Escherichia coli: a prospective, multicentre, observational cohort study. Bollestad M; Grude N; Solhaug S; Raffelsberger N; Handal N; Nilsen HS; Romstad MR; Emmert A; Tveten Y; Søraas A; Jenum PA; Jenum S; Møller-Stray J; Weme ET; Lindbaek M; Simonsen GS; J Antimicrob Chemother; 2018 Sep; 73(9):2503-2509. PubMed ID: 29982514 [TBL] [Abstract][Full Text] [Related]
88. Epidemiology, risk factors and comorbidity for urinary tract infections caused by extended-spectrum beta-lactamase (ESBL)-producing enterobacteria. Briongos-Figuero LS; Gómez-Traveso T; Bachiller-Luque P; Domínguez-Gil González M; Gómez-Nieto A; Palacios-Martín T; González-Sagrado M; Dueñas-Laita A; Pérez-Castrillón JL Int J Clin Pract; 2012 Sep; 66(9):891-6. PubMed ID: 22897466 [TBL] [Abstract][Full Text] [Related]
89. The importance of gender-stratified antibiotic resistance surveillance of unselected uropathogens: a Dutch Nationwide Extramural Surveillance study. den Heijer CD; Penders J; Donker GA; Bruggeman CA; Stobberingh EE PLoS One; 2013; 8(3):e60497. PubMed ID: 23555983 [TBL] [Abstract][Full Text] [Related]
90. Multidrug resistance and risk factors associated with community-acquired urinary tract infections caused by Escherichia coli in Venezuela. Guzmán M; Salazar E; Cordero V; Castro A; Villanueva A; Rodulfo H; De Donato M Biomedica; 2019 May; 39(s1):96-107. PubMed ID: 31529852 [TBL] [Abstract][Full Text] [Related]
91. Non-carbapenem antimicrobial therapy in young infant with urinary tract infections caused by community-acquired extended-spectrum β-lactamase-producing Escherichia coli. Jo KJ; Yoo S; Song JY; Kim SH; Park SE Pediatr Neonatol; 2021 May; 62(3):271-277. PubMed ID: 33602619 [TBL] [Abstract][Full Text] [Related]
92. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases. Tsui K; Wong SS; Lin LC; Tsai CR; Chen LC; Huang CH J Microbiol Immunol Infect; 2012 Jun; 45(3):193-9. PubMed ID: 22580086 [TBL] [Abstract][Full Text] [Related]
93. Low relapse rate of urinary tract infections from extended-spectrum beta-lactamase-producing bacteria in young children. Hyun HS; Kim JH; Cho MH; Park E; Ha IS; Cheong HI; Kang HG Pediatr Nephrol; 2019 Nov; 34(11):2399-2407. PubMed ID: 31270617 [TBL] [Abstract][Full Text] [Related]
94. Control of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a children's hospital by changing antimicrobial agent usage policy. Lee J; Pai H; Kim YK; Kim NH; Eun BW; Kang HJ; Park KH; Choi EH; Shin HY; Kim EC; Lee HJ; Ahn HS J Antimicrob Chemother; 2007 Sep; 60(3):629-37. PubMed ID: 17599919 [TBL] [Abstract][Full Text] [Related]
95. Antibiotic resistance of Escherichia coli isolated from uncomplicated UTI in general practice patients over a 10-year period. van Driel AA; Notermans DW; Meima A; Mulder M; Donker GA; Stobberingh EE; Verbon A Eur J Clin Microbiol Infect Dis; 2019 Nov; 38(11):2151-2158. PubMed ID: 31440915 [TBL] [Abstract][Full Text] [Related]
96. Aminoglycoside therapy for childhood urinary tract infection due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae. Han SB; Lee SC; Lee SY; Jeong DC; Kang JH BMC Infect Dis; 2015 Oct; 15():414. PubMed ID: 26464143 [TBL] [Abstract][Full Text] [Related]
97. Clinical and molecular epidemiology of community-onset, extended-spectrum beta-lactamase-producing Escherichia coli infections in Thailand: a case-case-control study. Apisarnthanarak A; Kiratisin P; Saifon P; Kitphati R; Dejsirilert S; Mundy LM Am J Infect Control; 2007 Nov; 35(9):606-12. PubMed ID: 17980240 [TBL] [Abstract][Full Text] [Related]
98. Risk factors for community-acquired urinary tract infection caused by ESBL-producing bacteria in children. Kizilca O; Siraneci R; Yilmaz A; Hatipoglu N; Ozturk E; Kiyak A; Ozkok D Pediatr Int; 2012 Dec; 54(6):858-62. PubMed ID: 22882781 [TBL] [Abstract][Full Text] [Related]
99. Extended spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae isolated in a rural hospital. Basak S; Mallick SK; Bose S J Indian Med Assoc; 2009 Dec; 107(12):855-8. PubMed ID: 20509468 [TBL] [Abstract][Full Text] [Related]
100. Extended spectrum beta-lactamases (ESBL) in Escherichia coli and Klebsiella pneumoniae: trends in the hospital and community settings. Khanfar HS; Bindayna KM; Senok AC; Botta GA J Infect Dev Ctries; 2009 May; 3(4):295-9. PubMed ID: 19759493 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]